These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37702479)

  • 1. Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors.
    Nishiya A; Salles N; de Almeida-Neto C; Ferreira S; Nogueira F; Rocha V; Mendrone-Júnior A
    Transfusion; 2023 Nov; 63(11):2106-2113. PubMed ID: 37702479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undisclosed HIV status and antiretroviral therapy use among South African blood donors.
    van den Berg K; Vermeulen M; Louw VJ; Murphy EL; Maartens G
    Transfusion; 2021 Aug; 61(8):2392-2400. PubMed ID: 34224581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.
    Stramer SL; Glynn SA; Kleinman SH; Strong DM; Caglioti S; Wright DJ; Dodd RY; Busch MP;
    N Engl J Med; 2004 Aug; 351(8):760-8. PubMed ID: 15317889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: A qualitative study.
    van den Berg K; Murphy EL; Louw VJ; Maartens G; Hughes SD
    Transfus Med; 2023 Aug; 33(4):277-286. PubMed ID: 36799902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusion-Acquired HIV: History, Evolution of Screening Tests, and Current Challenges of Unreported Antiretroviral Drug Use in Brazil.
    Nishiya AS; Ferreira SC; Salles NA; Rocha V; Mendrone-Júnior A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of unreported HIV prophylaxis on the kinetics of post-blood donation HIV seroconversion.
    Nishiya AS; Salles NA; de Almeida-Neto C; Witkin SS; Ferreira SC; Nogueira FAH; Facincani T; Rocha V; Mendrone-Jr A
    Transfusion; 2021 Dec; 61(12):3488-3492. PubMed ID: 34617611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
    Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
    J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes.
    Vermeulen M; Lelie N; Coleman C; Sykes W; Jacobs G; Swanevelder R; Busch M; van Zyl G; Grebe E; Welte A; Reddy R
    Transfusion; 2019 Jan; 59(1):267-276. PubMed ID: 30265757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms.
    van den Berg K; Murphy EL; Maartens G; Louw VJ; Grebe E
    Vox Sang; 2024 Jun; 119(6):581-589. PubMed ID: 38622931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1/2 screening in blood centers: implementing a two-step serological screening assay approach to reduce donor deferral.
    Stoyanov E; Gozlan Y; Wax M; Levin E; Shvartz L; Shinar E; Mendelson E; Mor O
    Transfusion; 2019 Jun; 59(6):2054-2060. PubMed ID: 30893485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
    Fiedler SA; Oberle D; Chudy M; Scheiblauer H; Henseler O; Halbauer J; Heiden M; Funk M
    Vox Sang; 2019 Jul; 114(5):443-450. PubMed ID: 31012114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand.
    Apisarnthanarak A; Jirayasethpong T; Sa-nguansilp C; Thongprapai H; Kittihanukul C; Kamudamas A; Tungsathapornpong A; Mundy LM
    HIV Med; 2008 May; 9(5):322-5. PubMed ID: 18400079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.
    Custer B; Quiner C; Haaland R; Martin A; Stone M; Reik R; Steele WR; Kessler D; Williamson PC; Anderson SA; Williams AE; Raymond HF; McFarland W; Robinson WT; Glick S; Sey K; Melton CD; Glynn SA; Stramer SL; Busch MP
    Blood; 2020 Sep; 136(11):1351-1358. PubMed ID: 32645148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
    Hui X; Gan X; Li Q; Sun W
    Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors--an assessment of the efficacy of testing in donor screening. The HIV-Antigen Study Group.
    Alter HJ; Epstein JS; Swenson SG; VanRaden MJ; Ward JW; Kaslow RA; Menitove JE; Klein HG; Sandler SG; Sayers MH
    N Engl J Med; 1990 Nov; 323(19):1312-7. PubMed ID: 2120589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine HIV screening among blood donors in Buenos Aires (Argentina): results from six years' experience and report of a single window-period donation.
    Gendler SA; Pascuccio MS
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):82-90. PubMed ID: 17288905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group.
    Busch MP; Dodd RY; Lackritz EM; AuBuchon JP; Birkmeyer JD; Petersen LR
    Transfusion; 1997 Oct; 37(10):1003-11. PubMed ID: 9354817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of human immunodeficiency virus (HIV) infection among contemporary anti-HIV-1 and anti-HIV-1/2 supplemental test-indeterminate blood donors. The Retrovirus Epidemiology Donor Study.
    Busch MP; Kleinman SH; Williams AE; Smith JW; Ownby HE; Laycock ME; Lee LL; Pau CP; Schreiber GB
    Transfusion; 1996 Jan; 36(1):37-44. PubMed ID: 8607151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.